(Q33958570)

30 July 2017

1 reference

title

A systematic review of the use of atypical antipsychotics in autism (English)

1 reference

30 July 2017

0 references

1 reference

L Barnard

1

1 reference

30 July 2017

A H Young

2

1 reference

30 July 2017

J Pearson

3

1 reference

30 July 2017

J Geddes

4

1 reference

30 July 2017

G O'Brien

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Journal of Psychopharmacology

30 July 2017

1 reference

30 July 2017

16

1 reference

30 July 2017

1

1 reference

30 July 2017

93-101

1 reference

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.

30 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Risperidone for aggression and self-injurious behavior in adults with mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

The antipsychotics. A pediatric perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Use of risperidone in pervasive developmental disorders: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Consultation-liaison in child psychiatry: a review of the past 10 years. Part I: Clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Case study: risperidone treatment of children and adolescents with developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Risperidone and explosive aggressive autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Adverse effects of clomipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Olanzapine for autistic disorder with hyperactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Open-label quetiapine in the treatment of children and adolescents with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

An open trial of risperidone in young autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Executive functions and developmental psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Risperidone in the treatment of two very young children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Risperidone in the treatment of pervasive developmental disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

Psychopharmacology in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F026988110201600113

10.1177/026988110201600113

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference